Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cenerimod - Idorsia Pharmaceuticals

Next Previous
Drug Profile

Cenerimod - Idorsia Pharmaceuticals

Alternative Names: ACT-334441; Second selective S1P1 receptor agonist - Idorsia

Latest Information Update: 08 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Idorsia Pharmaceuticals
  • Class Oxadiazoles; Pyridines; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic lupus erythematosus
  • Preclinical Rheumatoid arthritis
  • No development reported Autoimmune disorders

Most Recent Events

  • 23 Sep 2025 Viatris plans a phase III trial for Lupus nephritis (Adjunctive treatment) (PO, Tablets) in December 2025 (NCT07201129)
  • 28 Feb 2025 Cenerimod licensed to Viatris in Japan, South Korea, and certain countries in the Asia-Pacific (APAC) region (excluding China)
  • 26 Feb 2025 Viatris and Idorsia update the terms of the global licensing agreement for the development and commercialisation of cenerimod and selatogrel

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top